Cannabis for Endometriosis - How Can It Help? Complete Guide 2026

Endometriosis affects about 10% of women and girls of reproductive age according to the World Health Organization, which is roughly 190 million people worldwide (WHO, 2025). There is no causal treatment, and available therapies are insufficient or poorly tolerated by some patients. In this gap, interest in cannabis grows: both medical marijuana with THC, dispensed on prescription, and CBD products available without prescription. This text gathers what research has truly shown and indicates where evidence ends and hope begins. It includes a description of changes in the endocannabinoid system in patients, a review of available clinical studies with their limitations, rules for access to medical marijuana in Poland, and reasons why no doses are provided here. The article is educational and does not replace consultation with the attending gynecologist.

KEY INFORMATION
- Endometriosis affects about 10% of women of reproductive age, approximately 190 million people (WHO, 2025).
- Women with endometriosis showed elevated plasma concentrations of anandamide and 2-AG with simultaneously lower CB1 receptor expression in endometrial stromal cells (Sanchez, Reproductive Sciences, 2016).
- In an Australian survey of 484 patients, cannabis was the highest-rated self-help method for pain relief, with an average of 7.6 out of 10 points (Armour, BMC Complementary and Alternative Medicine, 2019).
- A systematic review from 2026 found nine completed studies, all cross-sectional. There are no randomized placebo-controlled trials (McLaren, Australian and New Zealand Journal of Obstetrics and Gynaecology, 2026).
- This guide does not provide any doses. EFSA states that CBD safety cannot be established in people taking medications, which is the case for most patients with endometriosis (EFSA Journal, 2026).
- Cannabis does not cure endometriosis causally and does not replace gynecological care or surgery (ESHRE, 2022).

What is endometriosis and who does it affect?

Endometriosis is a chronic disease in which tissue similar to the uterine lining grows outside the uterine cavity. The World Health Organization estimates it affects about 10% of women and girls of reproductive age, corresponding to roughly 190 million people worldwide (WHO, 2025).

Lesions most often appear on the ovaries, pelvic peritoneum, in the rectovaginal pouch, and on the uterosacral ligaments. Less commonly, they involve the intestine, urinary bladder, or diaphragm. Each lesion follows the same hormonal rhythm as the endometrium in the uterus, so it bleeds and causes a local inflammatory reaction. Repeated cycles of inflammation and healing lead to adhesions that immobilize pelvic organs relative to each other.

The disease is estrogen-dependent, so its course usually worsens during reproductive age and eases after menopause. The anatomical stage does not directly correlate with symptom severity. A patient with a few small lesions may suffer more than a woman with extensive disease found incidentally during infertility diagnostics. This is one reason why the clinical picture matters as much as the surgical one in this disease.

Poland does not maintain an endometriosis registry, so the national patient number cannot be given from any hard source. Applying the WHO percentage to the population of women of reproductive age yields an order of magnitude from hundreds of thousands to over a million people, but this is an estimate derived from a percentage, not a measurement result. Any number given for Poland should be read with this caveat.

A separate issue is adenomyosis, in which tissue similar to endometrium invades the uterine muscle wall. It is sometimes diagnosed alongside endometriosis but is a distinct entity with a different picture and management. The distinction is practically important because some descriptions circulating online mix both diseases, and conclusions about the effectiveness of any method transferred between them become unreliable.

What symptoms does endometriosis cause?

Endometriosis symptoms are varied and easily confused with bowel or urinary tract diseases. The World Health Organization lists severe menstrual pain, chronic pelvic pain, pain during intercourse, pain during urination and defecation, bloating, nausea, fatigue, and difficulty conceiving (WHO, 2025).

Painful periods are the most common reason for seeing a doctor but are also often underestimated. In many families and clinics, severe menstrual pain is still considered normal rather than a symptom requiring diagnosis. This belief costs patients years.

The second group of symptoms is non-menstrual. Pain persists through most of the cycle, worsens with physical exertion, prolonged standing, or after meals. Bowel symptoms can closely mimic irritable bowel syndrome, especially when they worsen around menstruation. Pain during intercourse, especially deep pain, is usually associated with lesions in the posterior pelvic compartment and is often the hardest for patients to report.

The third group is distant effects: chronic fatigue, sleep disturbances, low mood, and anxiety. These are not an addition to the disease or a hypersensitive psyche reaction but a natural consequence of years of pain and diagnostic uncertainty. The World Health Organization lists mental health impact alongside somatic symptoms. Endometriosis can also cause infertility, though not every patient has this problem.

From the patient’s perspective, the most practical thing is symptom tracking. Recording cycle day, pain intensity, location, and circumstances that worsen it provides the doctor with material that cannot be recalled from memory during a short visit. Such tracking also helps distinguish cycle-dependent symptoms from those persistent regardless of the cycle, guiding further diagnostics.

How is endometriosis diagnosed?

Diagnosis is based on history, gynecological examination, and imaging studies, and the role of diagnostic laparoscopy has changed in recent years. The European Society of Human Reproduction and Embryology guidelines issued on February 2, 2022, fully revise the 2014 version and introduce significant changes in recommendations regarding the role of diagnostic laparoscopy and postoperative hormone therapy (ESHRE, 2022).

The practical effect is that diagnosis no longer needs to be postponed until surgery. Transvaginal ultrasound performed by an experienced person detects endometrial cysts on ovaries and some deep lesions. Magnetic resonance imaging complements the picture where bowel, bladder, or retroperitoneal space involvement is suspected. A negative imaging result does not exclude disease, especially with superficial lesions.

Blood tests do not resolve diagnosis. There is no marker with sufficient sensitivity and specificity for endometriosis diagnosis, and CA-125 testing yields too many false positives and negatives to base decisions on. This lack is a main cause of diagnostic delay.

From first symptoms to diagnosis usually takes many years. Several factors contribute simultaneously: nonspecific symptoms, overlap with gastrointestinal diseases, normalization of menstrual pain, and short typical outpatient visit time, making it hard to gather cycle and sexual life history. This text does not give a specific number of years because ranges repeated online have no source applicable to Polish conditions.

It is worth knowing how extensive the document cited here is. The 2022 guidelines contain over a hundred recommendations on care for women with endometriosis, covering both diagnostic procedures and treatment aimed at pain relief and infertility. They fully replace the previous versions from 2013 and 2014, so references to older guidelines are now outdated.

Where does pain in endometriosis come from?

Pain in endometriosis has at least three layers, explaining why one treatment method rarely suffices. The first layer is inflammatory: lesions bleed cyclically and release mediators that irritate nerve endings. The second is neurogenic, and the third involves the central nervous system.

Rat model studies showed that endometrial lesions become innervated. Sensory and sympathetic fibers grow into abnormal growths, and cannabinoid CB1 receptors are found both on cell bodies and fibers of these neurons (Dmitrieva, Pain, 2010). This means the lesion is not a passive tissue fragment but a structure connected to the nervous system.

The third layer is central sensitization. After years of repeated pain stimuli, the spinal cord and brain begin to amplify rather than suppress the signal. A stimulus previously neutral becomes painful. This mechanism explains a surprising observation for patients: removing all visible lesions does not always end pain. Surgery removes the stimulus source but does not reverse changes in conduction pathways.

Cannabinoids interest focuses on this third layer. Not because they would remove lesions but because the endocannabinoid system participates in pain conduction regulation at spinal and brain levels. This narrows realistic expectations: we talk about modulation of perception, not disease treatment.

This three-layer picture also explains why painkillers alone stop working for some patients. They mainly act on the inflammatory layer, and with a dominant central component, their effectiveness decreases. Hence modern guidelines emphasize multimodal management, combining pharmacotherapy with pelvic floor physiotherapy and psychological support focused on coping with chronic pain.

How does the endocannabinoid system change in endometriosis?

Changes are documented and go in two directions simultaneously. A study comparing 27 women with laparoscopically confirmed endometriosis to 29 women without endometrial pathology found elevated plasma concentrations of anandamide, 2-arachidonoylglycerol, and oleoylethanolamide in the secretory phase, with simultaneously lower CB1 receptor expression in endometrial stromal cells than controls (Sanchez, Reproductive Sciences, 2016).

The authors interpret this as negative feedback. The body raises circulating levels of its own cannabinoids, but tissue responds by reducing receptor numbers, so the signal does not translate into effective pain control. This distinction is important because popular texts simplify endometriosis as simply an endocannabinoid deficiency. The measurement says otherwise: substances are increased, but tissue response is decreased.

In the same study, patients with moderate and severe menstrual pain and pain during intercourse had higher levels of anandamide and palmitoylethanolamide, respectively, than those with milder symptoms. The relationship between symptom and mediator exists not only at the group level but also within the patient group. More about how anandamide levels change in the normal cycle can be found in a separate text on the endocannabinoid system in the menstrual cycle.

Practical conclusions from these data are cautious. They show the endocannabinoid system is truly disturbed in endometriosis and is a reasonable pharmacological target. They do not show that administering a plant cannabinoid restores balance or what form such treatment would take.

Equally important is what the study did not find. CB2 receptor expression, TRPV1 receptor, and enzymes responsible for anandamide synthesis and degradation were comparable in stromal cells of patients and controls. The disturbance did not involve the entire system but a selected fragment. Popular descriptions claiming dysregulation of all endocannabinoid system elements go beyond what this measurement allows.

Is there an endocannabinoid deficiency?

The concept of clinical endocannabinoid deficiency was proposed in 2004 by Ethan Russo. He hypothesized that migraine, fibromyalgia, and irritable bowel syndrome share a common denominator of endocannabinoid system dysfunction, linked by chronic pain without clear structural damage (Russo, Neuro Endocrinology Letters, 2004).

Two points should be noted immediately. First, endometriosis is not mentioned among example syndromes in that paper’s abstract. Including it in this family is a later hypothesis extension, not a 2004 finding, and should be described as such. Second, Russo formulated it as a concept to be tested, suggesting cerebrospinal fluid studies and neuroimaging as verification methods.

A review on endocannabinoids in endometriosis pain treatment describes the system as a promising pharmacological target due to the complexity of pain mechanisms in this disease (Bouaziz, Cannabis and Cannabinoid Research, 2017). It is a review paper, so it provides no original measurements and is cited here accordingly.

For patients, the difference between hypothesis and finding matters. The statement “endometriosis is an endocannabinoid deficiency supplemented by cannabis preparation” sounds like a diagnosis and prescription in one but is currently only a research model. Plasma measurement data described earlier contradict the simple version of this story.

After two decades, the topic remains unresolved, though the concept has spread in popular texts, usually without this caveat or reference to the original paper. For readers, this means any encountered statement about endocannabinoid deficiency in endometriosis does not come from endometriosis research but from transferring a hypothesis formulated for other pain syndromes.

What do clinical studies say about cannabis in endometriosis?

The strongest available data come from surveys and app record analyses, not randomized trials. An Australian online survey collected 484 valid responses from women with confirmed endometriosis. Self-help methods were used by 76%, most often heat, rest, and breathing exercises or meditation. Cannabis was rated highest for pain relief effectiveness (Armour, BMC Complementary and Alternative Medicine, 2019).

The cannabis analysis of the same survey showed 13% of women using any self-help used cannabis, with a pain reduction effectiveness rating of 7.6/10. Over half, exactly 56%, reduced medication intake by at least half. The greatest improvement was reported in sleep and nausea/vomiting, and adverse effects occurred in 10%, mild (Sinclair, Journal of Obstetrics and Gynaecology Canada, 2020).

The data collection method matters for interpretation. The survey was distributed via social media by Australian patient organizations from October to December 2017, and participation was open to women aged 18 to 45 with confirmed endometriosis. This is a convenience sample, not random, so responses describe an engaged subset of patients, not the entire patient population.

What did the app-based symptom tracking study show?

It showed how women actually use cannabis, not whether it works. The cohort study based on app records included 252 people declaring endometriosis who registered 16,193 use sessions between April 2017 and February 2020 (Sinclair, PLOS ONE, 2021). These are retrospective data self-entered by users without a control group.

The most common administration route was inhalation, chosen in 67.4% of sessions, and pain was the most frequently treated symptom, indicated in 57.3% of records. More interesting is the result for gastrointestinal symptoms: they were a less common reason for use (15.2% of sessions) but showed the greatest reported improvement.

A practical observation concerns administration route. Inhaled forms performed better for pain, oral forms for mood and gastrointestinal symptoms, explained by authors as due to onset speed. The THC to cannabidiol ratio had a statistically significant but clinically small effect. Authors note clinical trials in this indication are urgently needed.

A limitation is inherent in the method. Data were self-reported before and after sessions, so the effect of the preparation cannot be separated from expectations or natural pain course. Also, users for whom the preparation did not help tend to stop using the app and thus drop out.

What remains unknown despite these studies?

The most important unknown is whether cannabis works better than placebo in endometriosis. All results described above, including the app record analysis, come from studies without a comparison group. They show why patients use the preparation and how they rate it, not the substance’s effect itself.

A systematic review published in 2026 summarizes this body of work without embellishment. Authors found thirteen studies, including four ongoing. All nine completed studies were cross-sectional and included 1787 participants. Pain was the most common reason for cannabis use, ranging from 57.3% to 95.5% depending on the study. Adverse effects were reported by 10.2% to 52.0%, most often intoxication sensation and dry mouth (McLaren, Australian and New Zealand Journal of Obstetrics and Gynaecology, 2026).

The review authors’ conclusion is clear: prospective longitudinal studies and randomized trials are lacking to assess efficacy and safety. Remember this when reading any material about cannabis in this disease, including this one. All available results are self-assessments by people who chose this method themselves, which inherently inflates the effect.

They also highlight a technical issue with major consequences. Studies assessed efficacy by such varied methods that results could not be combined into a single number. Eight of thirteen studies asked participants about subjective efficacy, each using a different scale. Therefore, this text presents results separately for each study instead of averaging them.

What do animal studies show?

Animal models tell more about mechanisms than human efficacy but justified further research. In a rat model, CB1 receptor agonists reduced pain hypersensitivity associated with endometriosis, and antagonists increased it. Authors also showed CB1 receptors on sensory and sympathetic neurons innervating lesions (Dmitrieva, Pain, 2010).

A second study tested pure THC in a surgically induced mouse endometriosis model. Mice with lesions developed mechanical hypersensitivity of the abdominal wall, mild anxiety-like behavior, and clear memory deficits. Repeated THC administration reduced mechanical hypersensitivity and pain unpleasantness, altered uterine innervation, and restored cognitive function but did not change anxiety behavior. Importantly, it also inhibited endometrial cyst development (Escudero-Lara, eLife, 2020).

This last finding is sometimes cited as evidence that cannabis “reduces lesions.” Caution is warranted for three reasons: the study was in mice, not women; it involved pure THC, not CBD products; and it measured lesion development from the start, not regression of existing lesions. Authors explicitly call for clinical trials, not therapeutic recommendations.

Also remember doses used in such models. Converting mouse doses to human is not simple multiplication and gives no practical guidance. Thus, animal results are suitable for mechanism description and justifying further research but not for planning personal therapy.

The mouse model is worth another note. Besides pain hypersensitivity, animals developed clear memory deficits, a symptom often omitted or dismissed as fatigue in human disease descriptions. Cognitive restoration after THC was a separate outcome alongside pain effects. Whether this translates to humans remains an open question.

Does CB1 receptor stimulation always reduce lesions?

No, and this is the most important caveat in all preclinical material. In a randomized mouse model study, animals receiving the CB1 receptor agonist methanandamide developed lesions with significantly larger volume than controls. Lesions also showed increased expression of genes linked to cell survival and migration, including survivin, N-cadherin, integrin beta 1, and interleukin 6 (Human Reproduction, 2017).

The second part of the same study closes the issue from the other side. CB1 receptor knockout mice developed smaller lesions with lower expression of the same genes, regardless of whether the receptor was missing in donor tissue, recipient, or both. In other words, removing CB1 signaling inhibited disease development, and enhancing it worsened it.

Combined with the previous section, this gives a picture that cannot be summarized simply. The same receptor mediated pain hypersensitivity reduction in one model, lesion growth inhibition in another, and lesion enlargement in a third. Authors note that translating results to humans requires further research. Until then, the promise “cannabinoids reduce lesions” lacks even animal data support.

What is the difference between medical marijuana with THC and CBD?

They are two different paths, differing in legal status, production method, and action profile. THC is psychoactive, directly stimulates CB1 receptor, and in Poland is available only on prescription as a pharmaceutical raw material for magistral preparations. CBD is non-psychoactive, does not directly stimulate CB1 or CB2 receptors, and is sold without prescription as a consumer product ingredient.

Observational data do not resolve which path is more effective. The significance of the THC to cannabidiol ratio is described above in the app-based symptom tracking study section, which adds it also depends on administration route (Sinclair, PLOS ONE, 2021). In other words, the difference is measurable but small compared to interindividual differences.

If you are interested only in the over-the-counter path, it is described separately in the text on CBD for endometriosis. There you will find a narrower approach to the same topic without parts about THC and prescriptions.

There is also a difference in composition. Full-spectrum products contain the main cannabinoid plus accompanying compounds, including trace THC, while isolates contain a single compound. The app record analysis registered both strain and cannabinoid ratio, allowing assessment of this ratio’s impact on reported efficacy. However, the manufacturer’s declaration does not replace laboratory testing of a batch. For patients, the difference boils down to who is responsible for quality: with magistral preparations, the raw material approval system and pharmacy ensure it; with consumer products, responsibility is distributed differently, and verification tools on the buyer’s side are practically absent.

How is access to medical marijuana in Poland?

The basis is the Act of July 7, 2017, published in Dz.U. 2017 item 1458 and effective from November 1, 2017. It introduced the possibility of using cannabis herb other than fiber hemp as a pharmaceutical raw material for magistral preparations. This is regulated by Article 33a of the Act on Counteracting Drug Addiction, and introducing raw material to the market requires permission from the Office for Registration of Medicinal Products.

The practical patient pathway is: medical consultation, assessment of previous treatment and contraindications, then an Rpw prescription issued electronically. It is dispensed in a pharmacy authorized to dispense narcotics, and the medicine is prepared on-site from raw material. Regulations do not limit authorization to one specialty, so the attending doctor may issue the prescription if deemed appropriate. This procedure is described in detail in the text on obtaining a medical marijuana prescription.

The therapy is not reimbursed, so the patient bears the cost. This text does not provide specific amounts because raw material and magistral preparation prices change faster than the article, and giving an unconfirmable number would be misinformation, not help. The current price is given by the dispensing pharmacy.

Availability of particular raw materials varies and depends on import. It is worth asking the pharmacy before seeing the doctor because the prescription is issued for a specific raw material. Changing raw material requires a new prescription, not a substitution at the counter.

One more detail is worth knowing. The Office for Registration of Medicinal Products issues raw material marketing authorization for five years, and each raw material undergoes this procedure separately. From the patient’s perspective, this means the catalog of available raw materials changes over time, and magistral preparations are not ready-made products bought off the shelf but prepared in the pharmacy based on a specific prescription.

Is over-the-counter CBD legal in Poland?

Yes, if the product comes from fiber hemp varieties within the THC content threshold. The national threshold is 0.3%, counted as the sum of delta-9-THC and tetrahydrocannabinolic acid, rounded to one decimal place. This distinction matters practically because it changes the lab test result: delta-9-THC alone gives a lower value than the sum of both compounds.

The national basis is Article 4 point 5 of the Act on Counteracting Drug Addiction as amended by the Act of March 24, 2022, published in Dz.U. 2022 item 763. Previously, the national threshold was 0.2%. The 0.3% value also appears in EU law, Regulation 2021/2115, but these are two separate regulations with the same numeric value. It is correct to say the national threshold corresponds to the EU threshold, not that it derives from it.

Separately, note that the August 27, 2026 amendment did not change the THC content threshold, substance classification, or retail sale rules. The state described above remains valid after that date.

Below this threshold are semi-synthetic derivatives sometimes asked about by patients seeking stronger over-the-counter options. HHC is a controlled substance and does not have consumer product status, so it is not an alternative to the legal medical path.

The practical conclusion for buyers is that the compliance declaration refers to the plant raw material, not automatically to the finished product. Full-spectrum products contain trace THC amounts, which matters for substance detection tests. The threshold calculation method, summing delta-9-THC and its acid form, is not a formality but a difference in test results.

Why does this guide not provide doses?

Because in disease, dose is a doctor’s decision, not information safely given collectively. The European Food Safety Authority in a 2026 updated opinion states CBD safety cannot be established in people under 25 years old. The same applies to pregnant and breastfeeding women and people taking medications (EFSA Journal, 2026).

The last group describes most readers of this text. Patients with endometriosis usually take painkillers, often hormonal preparations, and sometimes antidepressants or anxiolytics. The EFSA panel notes hepatotoxicity signals in human studies especially when CBD was used with other drugs.

Two more caveats from this document are worth knowing. The provisional safe dose was derived by benchmark dose method with an uncertainty factor of 400, indicating high data uncertainty. It applies only to supplements with at least 98% pure CBD, without nanoparticles, and excluded genotoxicity. Full-spectrum and broad-spectrum products, most commonly used, do not fit this description.

For these reasons, you will not find milligram, gram of herb, or drop counts here. Dose discussion belongs in the clinic, where someone knows your medication list, test results, and disease course. Any text giving you a ready dose for the disease omits precisely this knowledge.

The uncertainty scale directly results from the list of gaps the panel mentions. Unresolved are effects on liver and gastrointestinal tract, hormonal system, nervous and reproductive systems. Neurological and psychiatric safety data are insufficient, and immune system effects were not studied. With such knowledge status, giving a ready number would be pretending certainty regulators do not have.

Which symptoms respond best to cannabis?

Data allow symptom ranking but only by patient self-assessment. In the Australian survey, greatest improvement was reported in sleep and nausea/vomiting, with overall pain relief rating 7.6 out of 10 (Sinclair, Journal of Obstetrics and Gynaecology Canada, 2020).

Rows marked Sinclair 2021 come from the app-based symptom tracking study described above.

What is missing in these data is equally important. There is no evidence of effect on lesions or fertility in humans. There is also no placebo comparison, so part of reported improvement cannot be separated from expectations of a person consciously choosing this method and recording their own result.

Symptom order in this table should be read cautiously. Each study measured efficacy by different methods, so numbers from different works are not directly comparable, and the 2026 review authors explicitly advise against combining them. The table orders observation directions, not effect strength, and is not suitable for predicting individual response. One pattern stands out: areas with greatest reported improvement do not coincide with those most often treated.

How does cannabis relate to hormone therapy?

These two strategies do completely different things and are not substitutes. Hormonal treatment acts on the disease: it suppresses the cycle, lowers estrogen stimulation, and limits lesion activity. Cannabis acts on symptoms, primarily pain perception, sleep, and bowel symptoms. European guidelines from 2022 place hormonal and pain treatments in first-line management (ESHRE, 2022).

The problem that actually drives patients to seek alternatives is hormone therapy intolerance. Mood changes, spotting, headaches, or libido decrease can cause therapy discontinuation. The proper answer is not “replace hormones with cannabis” but “return to the doctor,” as several hormonal regimens exist with different tolerability.

There is also a less often mentioned risk. EFSA’s position points to hepatotoxicity signals with simultaneous CBD and other drug use, and hormone therapy is such concurrent treatment. Adding CBD preparation to hormone therapy independently is therefore not a neutral step and requires the attending doctor’s knowledge.

The practical conclusion is simple. If hormone therapy works but does not fully relieve pain, discussing additional support makes sense. If hormone therapy is poorly tolerated, the first step is its modification by a doctor, not replacement with a self-purchased product.

Another reason not to decide alone lies in the guidelines. The 2022 revision changed recommendations on postoperative hormone therapy, an area where patients most often seek additional support. Postoperative management is now different than a decade ago, and older information still online can mislead. When reading endometriosis materials, check which guideline version they cite, as publication date alone does not indicate source date.

When is surgery needed, not cannabis?

Surgery remains a treatment method, and no symptomatic preparation replaces it. European guidelines from 2022 include surgical management alongside pharmacological in two separate parts: one focused on pain relief and one on infertility related to endometriosis (ESHRE, 2022). The change in this version concerns laparoscopy’s role as a diagnostic tool, not abandoning surgical treatment.

There are also situations where delay is dangerous. Symptoms of bowel obstruction, blood in urine or stool, rapid cyst enlargement, or disabling pain require urgent medical evaluation. In these circumstances, using anything that only masks pain delays diagnosis of real complications.

The perioperative period follows separate rules. Information about cannabis preparations, including over-the-counter ones, belongs to preoperative history equally with medication lists. The anesthesiologist decides when and for how long to stop them before anesthesia, depending on preparation type, administration route, and other drugs, not the article author.

After surgery, chronic pain persisting despite lesion removal is common. This group most often seeks cannabis information, and all caution described here applies: evidence is observational, and the decision to try belongs to the care team.

Infertility related to endometriosis is a separate pathway. European guidelines cover it in a separate recommendation part alongside pain management because decisions can conflict: what helps pain may not support conception. If planning pregnancy, inform before treatment planning, not after starting. This single piece of information changes both action order and drug choice, and with cannabis preparations, it is decisive since they are contraindicated in pregnancy and breastfeeding.

What drug interactions must be considered?

The most important information is general, not detailed: cannabinoids interact with drugs metabolized in the liver, and the medication list for endometriosis is usually long. The EFSA panel stated CBD safety cannot be established in people taking medications simultaneously and separately noted liver damage signals appeared especially with such combinations (EFSA Journal, 2026).

Popular materials mention dose thresholds below which interactions supposedly do not occur. You will not find such thresholds here because they lack support in documents used here. Giving a numeric limit also suggests a safe level independent of the individual patient, liver function, and other drugs, which is misleading.

Practically, this means three things. First, the intention to use a CBD product must be told to the attending gynecologist, even if the product is over-the-counter. Second, decisions with pain, antidepressant, and hormone treatments are individualized. Third, worsening well-being after adding the preparation is a reason to contact a doctor, not to increase the dose.

Absorption variability adds complexity. EFSA noted CBD bioavailability varies depending on carrier and whether taken with food. The same amount can yield different blood levels depending on intake circumstances, further complicating interaction prediction and arguing for doctor supervision, not self-experimentation.

Is CBD safe when trying to conceive?

There is no basis to claim so. EFSA in a 2026 opinion stated CBD safety cannot be established in pregnant and breastfeeding women, listing placental transfer and neurodevelopmental effects observed after prenatal exposure (EFSA Journal, 2026). The panel also noted hormonal disturbances, including thyroid hormone changes.

The same direction is FDA’s position. The Food and Drug Administration explicitly advises against cannabis and CBD use during pregnancy and breastfeeding (FDA, 2019), and conception attempts directly precede this period.

A separate question is conception itself. A review of endocannabinoid signaling in female reproduction describes their role in follicle and oocyte maturation, fertilization, tubal transport, and implantation, noting contradictory results between species (Progress in Lipid Research, 2020). Authors also point to possible epigenetic effects during pregnancy.

Practically, this means a woman with endometriosis planning pregnancy should discuss CBD use with her doctor before trying, not after. Pelvic pain in this period is managed by methods agreed with the gynecologist, as endometriosis and infertility treatment intertwine.

What limitations must not be overlooked?

The first and most serious limitation: there is not a single randomized placebo-controlled trial evaluating cannabis in endometriosis. All clinical evidence comes from observational studies, summarized with review authors’ conclusions in the section above on what remains unknown despite these studies.

The second limitation concerns adverse effects. They were reported by participants in studies included in the review, with rates varying so much between studies that a single number for the whole set cannot be given. The range and most common complaints are given in the same section above.

The third limitation is practical and concerns life outside the clinic. THC-containing preparations can cause positive test results, which matters for professional drivers, athletes under anti-doping control, and some regulated professions. Positive results are also possible with some full-spectrum products due to trace THC amounts.

The fourth limitation is cost and access inequality. Therapy is not reimbursed, and over-the-counter products vary in quality, with patients lacking tools to verify it independently. All this means cannabis should be treated as possible care supplementation, not a substitute.

The picture may still change. Some studies included in the 2026 review were ongoing at publication, so some answers will appear later. This argues against proclaiming a breakthrough today or definitively closing the topic. A responsible approach is to follow results, not anticipate them with speculation.

How to live with endometriosis daily?

Daily self-help is the norm, not the margin, in this disease. In the Australian survey, 76% used any self-help methods. Most often heat (70%), rest (68%), and meditation or breathing exercises (47%) (Armour, BMC Complementary and Alternative Medicine, 2019).

For pain relief effectiveness, cannabis ranked highest, followed by heat, dietary changes, and hemp or CBD oil. Movement interventions like yoga, stretching, and exercise were rated lower. The same study notes adverse events were frequent with alcohol and physical exertion, reported by 53.8% and 34.2% of users, respectively.

The practical conclusion is less obvious than it seems. Exercise remains valuable for general health but requires intensity adjustment in women with endometriosis, as poorly chosen activity can worsen symptoms. Alcohol, often treated as relaxation, fares poorly in these data.

There is also a layer no survey can measure: urogynaecological physiotherapy for pelvic floor muscle overactivity and psychological support for chronic pain. Both act on mechanisms different from drugs and thus combine well.

The same authors conclude women with endometriosis have different needs than those with primary dysmenorrhea, so self-help methods, especially exercise-based, must consider symptom exacerbation risk. Transferring advice aimed at all women with painful periods is often inappropriate. Practically, this means choosing activity by small steps and observing reactions over several cycles rather than starting an intensive training plan that may worsen pain and cause quitting exercise.

Is it worth considering cannabis for endometriosis?

The honest answer is: it depends on expectations. If expecting disease arrest, the answer is no, and no available study changes that. If expecting support in coping with pain, sleep, and bowel symptoms, discussion makes sense but must be with the attending doctor.

The evidence state today is: we have a consistent biological signal of endocannabinoid system disturbances in patients, promising animal model results, and several surveys where women rate cannabis effectiveness highly. We have no randomized placebo-controlled trial, and all completed studies are cross-sectional. This asymmetry is the essence and should not be blurred.

Caution also has regulatory justification. EFSA’s current position says CBD safety cannot be established in people under 25, pregnant and breastfeeding women, and those taking medications. Patients with endometriosis usually fall into the last group, sometimes more than one.

Therefore, this guide ends not with a protocol but an organizational tip. Track symptoms and their rhythm, gather a list of all medications, and treat cannabis discussion as part of a treatment plan set with a gynecologist. This is the only way considering both available evidence and your individual situation.

It is also worth knowing what would have to happen to change this answer. The 2026 review authors say it plainly: prospective longitudinal studies and randomized trials assessing efficacy and safety are needed. Four such studies are ongoing. Until their publication, any text promising certainty on this topic, including this one, goes beyond available data.

Frequently Asked Questions

Do cannabis plants cure endometriosis?

No. They do not remove lesions or adhesions and do not replace gynecological care. Available studies are observational and describe symptom reduction reported by patients, primarily pain, sleep, and bowel symptoms. A systematic review from 2026 found not a single randomized placebo-controlled trial for this indication.

What cannabis doses are used for endometriosis?

This article deliberately does not provide them. EFSA states that CBD safety cannot be established in people taking medications, and patients with endometriosis usually take them. The dose is determined by a doctor who knows the medication list, disease course, and test results. A ready number given in the article omits precisely this information.

What is the difference between medical marijuana and over-the-counter CBD?

Medical marijuana is a pharmaceutical raw material dispensed on an Rpw prescription and processed in a pharmacy into a magistral preparation, and its psychoactive effect results from THC content. CBD products are available without a prescription, are non-psychoactive, and no one supervises their use except the buyer.

Do cannabis plants interact with hormonal medications?

Cannabinoids affect liver metabolism, and EFSA noted signals of liver damage especially when CBD was used together with other drugs. Therefore, the intention to use a CBD product must be reported to the attending gynecologist, even if the product is purchased without a prescription.

Do cannabis plants replace laparoscopy?

No. European guidelines from 2022 treat surgical treatment as a separate pathway alongside pharmacological treatment, and cannabis does not replace it. They may at most affect symptom perception. Alarm symptoms, such as blood in stool or signs of obstruction, require urgent medical evaluation, not self-managed pain relief.

Can cannabis be used when trying to conceive?

Cannabis is contraindicated during pregnancy and breastfeeding. EFSA notes CBD crosses the placenta and neurodevelopmental consequences observed after prenatal exposure in animal studies, and FDA advises against cannabis and CBD use in this period. Discuss procreative plans with a gynecologist before starting anything.

Which symptoms respond best?

In an Australian survey, the greatest improvement was reported in sleep and nausea/vomiting, with a pain relief effectiveness rating of 7.6 out of 10. In an analysis of app records, the greatest improvement was noted in gastrointestinal symptoms, although they were a less common reason for product use.

Can a CBD product cause a positive THC test?

Yes, this is possible with full-spectrum products that contain trace amounts of THC. This matters for professional drivers, athletes subject to anti-doping controls, and people in regulated professions. The manufacturer’s declaration does not replace testing, and the risk should be considered before starting use.

The article is informational and educational and does not constitute medical advice. Before starting cannabis or CBD for therapeutic purposes, consult a doctor, especially if taking other medications, pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-09-22